BSECompany Update2d ago · 16 Nov 2026, 06:52 pm
Investor Presentation-Quarter II of FY 2026-27, ended on September 30, 2026
Orchid Pharma Ltd · 524372
✦ AI Summary▲ PositiveResults
Orchid Pharma Ltd has released its Investor Presentation for Q2 FY 2026-27, showcasing its financial performance and business prospects. The company has made significant progress in its anti-infectives business, with a strong presence in regulated markets and a focus on long-term growth.
Analysis Scores
Earnings Impact8/10
Growth Catalyst9/10
Governance Concern2/10
Regulatory Risk3/10
Balance Sheet Risk5/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Investor Presentation
Attachments (1)
📄pdf
Download →
b1b3f007-d442-4de3-a55b-0f3bc3f2d5fb.pdf
View document text
OrchidPharm~W
-- A DhanukaGroup Company -----------------------'--------------
November 16, 2026
National Stock Exchange of India Limited, BSE Limited
Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers,
Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001
Symbol: ORCHPHARMA Scrip Code: 524372
Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Requlations, 2015
(ii) SEBI Circular No. SEBIIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026
dated January 30, 2026
Sub: Investors Presentation- Ouarter II of F.Y. 2026-27, ended on September 30,
2026 - Orchid Pharma Limited ("the Company")
Dear Sir/Madam,
With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of
Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-
2/CIR/P/2024/185 dated December 31, 2024 and in continuation to our earlier intimation,
dated November 12, 2026, regarding the Analysts/Investors Earning Call scheduled to be
held on November 17, 2026 at 04:30 P.M. (1ST), please find enclosed the Investors
Presentation, inter-alia, including the financial performance of the Company for the
Quarter-II of Financial Year 2026-27, ended on September 30, 2026.
The Investor Presentation is also made available on the website of the Company at
https:llwww.orchidpharma.com(jnvestors
You are requested to take the above intimation on record.
Thanking You,
For Orchid Pharma Limited
Kapil Dayya
Company Secretary & Compliance Officer
Mem. No.- F10698
Encl. as above
+91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994
Registered Office: Corporate Office:
Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.
FROM
Soil to Vial
Nature Inspired Fermentation KSMs & API API Formulations Finished Dosage
Origins & Biotransformation Process Manufacturing & Fill Finish For A Healthier World
Development
2026
Safe Harbor
This presentation and the accompanying slides (the “Presentation”), which have been prepared byOrchid Pharma Limited (the
“Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding
commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document
containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but
the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth,
accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive
and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any
omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business
prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of
future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These
risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various
international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully
implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and
advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as
well as other risks. The Company's levels of activity, performance or achievements could differ materially and adversely fromresults
expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information
contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation
are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any
representation of accuracy, timeliness or completeness.
2026 orchidpharma.com 02
Orchid Pharma Limited
A significantly large anti- A strong participant in
infectives business built on selected high-value and Positioned for sustained
an integrated foundation regulated opportunities long-term growth
Scale + Integration Regulated Markets Structural Growth
One of the most
1 3 5
integrated
anti-infective
platform globally
Built on 30 years of cephalosporin expertise.
Proven by EXBLIFEP -India's only novel antibiotic.
Anchored by India's only USFDA sterile cephalosporin approval.
Extending into AMR and regulated markets.
A differentiated cephalosporin A business combining scale,
platform spanning KSM to integration, innovation and
finished dosage disciplined expansion
Full Value Chain Four Pillars
2026 orchidpharma.com 03
Orchid is at an inflection point
The merger is complete and
the platform is coming
An Integrated
together as one
Cephalosporin
Platform
The core API business is ready
to create long-term value
Multiple growth engines are moving
from concept to execution across KSM,
FDF, and Innovative drug products
2026 orchidpharma.com 04
S T R A T E G I C A M A L G A M A T I O N
Two entities.
One Orchid.
DLL OPL
ORCHID
Dhanuka Laboratories Ltd. amalgamated into
Orchid Pharma Ltd. under the NCLT-sanctioned Scheme.
APPOINTED DATE EFFECTIVE DATE
1 April 2024 10 July 2026
2026 orchidpharma.com 05
EXBLIFEP · BUSINESS DEVELOPMENT
Signed licensing partnerships
Pharmasyntez Laboratorio Libra
RUSSIA · 1 MARKET LATIN AMERICA · 9 MARKETS
US$ 178 M US$ 80 M
Estimated sales potential Estimated sales potential
Markets Covered: Russian Federation Markets Covered: Chile · Uruguay · Panama · El Salvador · Guatemala ·
Ecuador · Honduras · Paraguay · Costa Rica
COMBINED US$ 258 M across 10 markets · 2 signed partners
2026 orchidpharma.com 06
Financial
Performance
Q2 FY27
2026 orchidpharma.com 07
Q2 FY27 Financial Performance : Standalone
(RsCr)
(Amt.in Cr.) Q2-27 Q2-26 % Change H1-27 H1-26 % Change
Revenuefrom
341 298 +14% 645 562 +15%
Operations
Other Income 29 16 +76% 39 32 +20%
COGS 208 207 413 390
Employee Exp 33 31 59 58
Other Exp 77 57 135 115
EBITDA 52 20 +148% 77 31 +151%
% to Sales 15% 7% 12% 5%
Interest 4 3 6 5 +21%
Depreciation 11 11 22 21
Exceptional Items – – – –
PAT 37 7 49 5
2026 orchidpharma.com 08
Q2 FY27 Financial Performance : Standalone
(Rs Cr)
Total Revenue EBITDA PAT
341 52 37
Q2FY26 Q2FY27
Q2FY26 Q2FY27
Q2FY26 Q2FY27
Gross Margin EBITDA Margin (%)
Q2FY26 Q2FY27 Q2FY26 Q2FY27
2026 orchidpharma.com 09
H1 FY27 Financial Performance : Standalone
(Rs Cr)
Total Revenue EBITDA PAT
645 77
H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27
Gross Margin EBITDA Margin (%)
2026 orchidpharma.com 010
H1FY26 H1FY27 H1FY26 H1FY27
Profit & Loss Statement (Standalone)
(Rs Cr)
Q2 FY27 Q1 FY27 Q2 FY26 H1 FY27 H1 FY26 FY26
Particulars
Sep 2026 Jun 2026 Sep 2025 Sep 2026 Sep 2025 Year ended
Income
Revenue from Operations 341.27 304.17 298.46 645.44 561.64 1,232.78
Other Income 28.63 10.05 16.29 38.68 32.34 56.49
Total Income 369.90 314.22 314.75 684.12 593.99 1,289.27
Expenses
Cost of Materials Con
[Showing first 8,000 characters — download PDF for full document]